Koyuan Pharmaceutical revises its performance forecast for 2025, expecting a 70%-80% year-on-year decrease in net profit.

Koyuan Pharmaceutical released a correction announcement for the 2025 performance forecast, expecting a net profit attributable to the shareholders of the listed company to be between 12.08 million and 18.13 million yuan, a year-on-year decrease of 70% to 80%. The companys original forecasted net profit was between 27.20 million and 39.29 million yuan, representing a year-on-year decrease of 35% to 55%.